BBTX

16.0002.89%

STOCKS | Bambusa Therapeutics Falls 7% on Debut After $168.9 Million IPO

Bambusa Therapeutics Inc. shares fell 7% in their trading debut after the early-stage biotech raised $168.9 million in a US initial public offering, Bloomberg reported. The company focuses on dermatology and autoimmune diseases.

Source: CoinLive The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.